RT Journal Article
SR Electronic
T1 Rapid implementation of mobile technology for real-time epidemiology of COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.02.20051334
DO 10.1101/2020.04.02.20051334
A1 David A. Drew
A1 Long H. Nguyen
A1 Claire J. Steves
A1 Jonathan Wolf
A1 Tim D. Spector
A1 Andrew T. Chan
A1 on behalf of the COPE Consortium
YR 2020
UL http://medrxiv.org/content/early/2020/04/06/2020.04.02.20051334.abstract
AB The rapid pace of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic (COVID-19) presents challenges to the robust collection of population-scale data to address this global health crisis. We established the COronavirus Pandemic Epidemiology (COPE) consortium to bring together scientists with expertise in big data research and epidemiology to develop a COVID-19 Symptom Tracker mobile application that we launched in the UK on March 24, 2020 and the US on March 29, 2020 garnering more than 2.25 million users to date. This mobile application offers data on risk factors, herald symptoms, clinical outcomes, and geographical hot spots. This initiative offers critical proof-of-concept for the repurposing of existing approaches to enable rapidly scalable epidemiologic data collection and analysis which is critical for a data-driven response to this public health challenge.One Sentence Summary COVID-19 symptom tracker for smartphonesCompeting Interest StatementTDS is a consultant to Zoe Global Ltd. JW is an employee of Zoe Global Ltd. DAD and ATC previously served as investigators on a clinical trial of diet and lifestyle using a distinct mobile application that was supported by Zoe Global Ltd. Other authors have no conflict of interest to declare.Clinical TrialNCT04331509Clinical Protocols http://www.monganinstitute/cope-consortium Funding StatementATC is the Stuart and Suzanne Steele MGH Research Scholar. Development of the COVID Symptom Tracker mobile app was supported in kind by Zoe Global Limited and grants from the Wellcome Trust (212904/Z/18/Z).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe welcome anyone who would like access to this growing dataset to join the COPE Consortium to gain access to the data following completion of a data use agreement. Details with how to become a member can be found at http://www.monganinstitute.org/cope-consortium.